<DOC>
	<DOCNO>NCT01078649</DOCNO>
	<brief_summary>The purpose study determine safety profile maximum dose Debio 1143 ( AT-406 ) give human . This study also design measure much Debio 1143 ( AT-406 ) get blood stream ( pharmacokinetics ) , Debio 1143 ( AT-406 ) interact protein related cancer drug target affect ( pharmacodynamics ) .</brief_summary>
	<brief_title>Dose Escalation Study Safety Tolerability AT-406 Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>Ascenta Therapeutics , Inc. conduct clinical trial compound Debio 1143 ( AT-406 ) , small molecule second mitochondria-derived activator caspase C ( Smac ) mimetic . In vivo vitro study demonstrate Debio 1143 ( AT-406 ) induce cell death several tumor model inhibit XIAP ( X link IAP ) , cIAP-1 ( cellular IAP-1 ) cIAP-2 ( cellular IAP-2 ) , thus release initiator effector caspases promote apoptosis . This protocol Phase I , dose-escalation , open-label , multi-center study conduct patient advance solid tumor lymphomas evaluate safety , tolerability pharmacology Debio 1143 ( AT-406 ) human administer orally .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Histologically confirm solid tumor lymphoma ; Locally advance metastatic disease life prolong therapy available standard therapy judge appropriate investigator ; Eastern Cooperative Oncology Group Performance Status ≤ 1 ; Adequate hematologic function indicate , ANC ≥ 1,500/mm3 , Hgb &gt; 9.0 g/dL , platelet count ≥ 100,000/mm3 Adequate renal liver function indicate serum creatinine ≤ 1.0 x ULN creatinine clearance &gt; 60 cc/min , serum albumin ≥ 3.0 gm/dL , total bilirubin &lt; 1.0 x ULN , AST ALT ≤ 2.5 x ULN ; Alkaline phosphatase ≤2.5 x ULN Negative Hepatitis B Hepatitis C test ; QTc interval ≤450ms . Radiation within 14 day study entry , thoracic radiation within 28 day study entry . Patients receive prior radiotherapy must discontinue steroid 14 day prior study entry clinically stable ; Not recover ≤ Grade 1 toxicity prior radiotherapy chemotherapy agent ; Use requirement use aspirin aspirin contain product &gt; 81 mg aspirin per day ; History gastrointestinal bleeding within 1 year ; History diabetes mellitus require treatment oral agent insulin ; Active rheumatoid arthritis , active inflammatory bowel disease , chronic infection , disease condition associate chronic inflammation ; Known suspect Wilson 's Disease , condition affect copper accumulation regulation ; Prior treatment IAP inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>smac mimetic</keyword>
	<keyword>IAP inhibitor</keyword>
	<keyword>Phase I</keyword>
	<keyword>Dose escalation</keyword>
</DOC>